Navigation Links
MDS Pharma Services Expands Presence in Latin America with Sao Paulo Office

KING OF PRUSSIA, PA, Jan. 28 /PRNewswire-FirstCall/ - MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, has established an office in Sao Paulo, Brazil, to provide expanded capabilities in global clinical trial management. The new office joins nearly two dozen other MDS Pharma Services late stage clinical trial management offices in 21 countries in Africa, Asia Pacific, Europe, Latin America and North America. The opening of the Sao Paulo office is a clear indicator of the growing importance of Latin America to the drug development industry and of MDS Pharma Services' commitment to offer its clients the advantages of conducting trials in the region.

"Our new office in Sao Paulo is a key component of our global expansion strategy. It allows MDS Pharma Services to provide clients access to a large diverse pool of clinical trial participants and abundant healthcare resources, including more than 237,000 qualified physicians and more than 46,000 health institutions," said MDS Pharma Services President David Spaight. "Thanks to this excellent infrastructure, clinical trials in Brazil have an impressive track record of strong enrollment rates and good patient compliance and retention. These are critical factors in allowing us to fulfill the MDS Pharma Services brand promise to deliver high-quality, on-time service to clients."

In addition to the new office in Brazil, MDS Pharma Services also offers clinical trial monitoring services from Latin American offices in Buenos Aires, Argentina; Santiago, Chile; Lima, Peru; and Mexico City, Mexico. Since 2002, the MDS Pharma Services team in Latin America has conducted 33 global studies in focus areas such as oncology, metabolic disorders, cardiovascular, vaccines and infectious diseases.

Drug development activity has exploded in Brazil, which experienced a 1000 percent increase in clinical trials between 1995 and 2000. It is estimated that 645 Phase I-IV clinical trials are currently taking place in Brazil. While the incidence of heart disease, arthritis, cancer and infectious diseases in Brazil is on par with the United States, a greater percentage of the Brazilian population is treatment-naive, providing a major source of potential adult and pediatric clinical trial participants who are not taking prescription drugs that could interact or interfere with the drug being tested. The Southern Hemisphere location is another reason to include Brazil and other Latin American countries in multi-center trials; these countries experience summer when it is winter in the Northern Hemisphere, allowing MDS Pharma Services to offer its clients year-round testing of drugs for seasonally induced conditions such as allergies and other respiratory indications.

About MDS Pharma Services

MDS Pharma Services is committed to delivering quality results on time. We offer a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With numerous facilities strategically located around the world, we apply advanced scientific and technological expertise throughout the drug discovery and development process - from lead optimization, pre-IND research, early clinical research (bioequivalence, phases I-IIa) and bioanalysis through to global clinical development (phases IIb-IV), central lab and centralized cardiac services. For more information, visit our website at

MDS Pharma Services is a business unit of MDS Inc. (TSX: MDS; NYSE: MDZ), a global life sciences company that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 5,500 highly skilled people in 28 countries. Find out more at or by calling 1-888-MDS-7222, 24 hours a day.

Source data - website

(x) 645 Phase I-IV studies currently taking place in Brazil p=SA

SOURCE MDS Pharma Services
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... the way that they are handling security in light of the recent terrorist attacks ... in an attempt to stop an attack from reaching U.S. soil. Especially around special ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss ... to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When ... said an inventor from Hillside, N.J. "Many people catch diseases simply from sitting ... individuals will always be protected from germs." , He developed the patent-pending QUDRATECS ...
(Date:11/27/2015)... ... ... The print component of “Supporting Our Caregivers” is distributed ... Minneapolis, South Florida, with a circulation of approximately 250,000 copies and an estimated ... media strategy and across a network of top news sites and partner media ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... On Tuesday, November 24, 2015, the ... Wright Medical Technology, Inc. for product liability and ... implant device, awarded $11 million in favor of ... and three days of deliberations, the jury found ... designed and unreasonably dangerous, and that Wright Medical ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
Breaking Medicine Technology: